In a report released yesterday, Charles Rhyee from TD Cowen maintained a Hold rating on Charles River Labs (CRL – Research Report), with ...

Transposagen Biopharmaceuticals Inc. signed an exclusive licensing deal with Charles River Laboratories International Inc. (NYSE:CRL) for lab rats. Under the agreement, Wilmington, Mass.- ...

James Foster; Chairman of the Board, President, Chief Executive Officer; Charles River Laboratories International Inc Flavia Pease; Chief Financial Officer, Corporate Executive Vice President ...

Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and ...

Charles River has been riding rough waters in 2024, and, as the CRO’s CEO predicted, the third quarter proved no exception. Excluding foreign currency translation, acquisitions and divestitures, ...

Charles River Laboratories International, Inc. (CRL) updated financial guidance for 2024. Revenue and non-GAAP earnings per share guidance have been narrowed and slightly raised from the midpoint ...

Charles River Laboratories International Inc (NYSE:CRL) exhibits resilience despite a challenging market environment. Strategic acquisitions and a diversified service portfolio position CRL for ...

Charles River Labs Q3 revenue of $1.01 billion surpassed expectations; however, revenue declined 1.6% YoY, and operating ...

Charles River Laboratories Intl ( (CRL)) has released its Q3 earnings. Here is a breakdown of the information Charles River Laboratories Intl presented to its investors. Charles River Laboratories ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a ...